Skip to main content

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.

Publication ,  Journal Article
Doraiswamy, PM; Sperling, RA; Coleman, RE; Johnson, KA; Reiman, EM; Davis, MD; Grundman, M; Sabbagh, MN; Sadowsky, CH; Fleisher, AS; Clark, CM ...
Published in: Neurology
October 16, 2012

OBJECTIVES: Florbetapir F 18 PET can image amyloid-β (Aβ) aggregates in the brains of living subjects. We prospectively evaluated the prognostic utility of detecting Aβ pathology using florbetapir PET in subjects at risk for progressive cognitive decline. METHODS: A total of 151 subjects who previously participated in a multicenter florbetapir PET imaging study were recruited for longitudinal assessment. Subjects included 51 with recently diagnosed mild cognitive impairment (MCI), 69 cognitively normal controls (CN), and 31 with clinically diagnosed Alzheimer disease dementia (AD). PET images were visually scored as positive (Aβ+) or negative (Aβ-) for pathologic levels of β-amyloid aggregation, blind to diagnostic classification. Cerebral to cerebellar standardized uptake value ratios (SUVr) were determined from the baseline PET images. Subjects were followed for 18 months to evaluate changes in cognition and diagnostic status. Analysis of covariance and correlation analyses were conducted to evaluate the association between baseline PET amyloid status and subsequent cognitive decline. RESULTS: In both MCI and CN, baseline Aβ+ scans were associated with greater clinical worsening on the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog (p < 0.01) and Clinical Dementia Rating-sum of boxes (CDR-SB) (p < 0.02). In MCI Aβ+ scans were also associated with greater decline in memory, Digit Symbol Substitution (DSS), and Mini-Mental State Examination (MMSE) (p < 0.05). In MCI, higher baseline SUVr similarly correlated with greater subsequent decline on the ADAS-Cog (p < 0.01), CDR-SB (p < 0.03), a memory measure, DSS, and MMSE (p < 0.05). Aβ+ MCI tended to convert to AD dementia at a higher rate than Aβ- subjects (p < 0.10). CONCLUSIONS: Florbetapir PET may help identify individuals at increased risk for progressive cognitive decline.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neurology

DOI

EISSN

1526-632X

Publication Date

October 16, 2012

Volume

79

Issue

16

Start / End Page

1636 / 1644

Location

United States

Related Subject Headings

  • Risk
  • Radiopharmaceuticals
  • Psychomotor Performance
  • Psychiatric Status Rating Scales
  • Predictive Value of Tests
  • Positron-Emission Tomography
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Male
  • Longitudinal Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., … AV45-A11 Study Group, . (2012). Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology, 79(16), 1636–1644. https://doi.org/10.1212/WNL.0b013e3182661f74
Doraiswamy, P Murali, Reisa A. Sperling, R Edward Coleman, Keith A. Johnson, Eric M. Reiman, Mat D. Davis, Michael Grundman, et al. “Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.Neurology 79, no. 16 (October 16, 2012): 1636–44. https://doi.org/10.1212/WNL.0b013e3182661f74.
Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012 Oct 16;79(16):1636–44.
Doraiswamy, P. Murali, et al. “Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.Neurology, vol. 79, no. 16, Oct. 2012, pp. 1636–44. Pubmed, doi:10.1212/WNL.0b013e3182661f74.
Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A11 Study Group. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012 Oct 16;79(16):1636–1644.

Published In

Neurology

DOI

EISSN

1526-632X

Publication Date

October 16, 2012

Volume

79

Issue

16

Start / End Page

1636 / 1644

Location

United States

Related Subject Headings

  • Risk
  • Radiopharmaceuticals
  • Psychomotor Performance
  • Psychiatric Status Rating Scales
  • Predictive Value of Tests
  • Positron-Emission Tomography
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Male
  • Longitudinal Studies